Gamma_NP Interferon_NP Inhibits_NP Production_NN of_IN Anti-OspA_JJ Borreliacidal_JJ Antibody_NN In_IN Vitro_NP The_DT ability_NN of_IN a_DT Lyme_NP borreliosis_NN vaccine_NN to_TO induce_VB and_CC maintain_VB sustained_JJ levels_NNS of_IN borreliacidal_JJ antibody_NN is_VBZ necessary_JJ for_IN prolonged_JJ protection_NN against_IN infection_NN with_IN Borrelia_NP burgdorferi_NP ._SENT Vaccination_NN against_IN infection_NN with_IN B._NP burgdorferi_NP could_MD be_VB improved_VBN by_IN determining_VBG the_DT mechanism(s)_NN that_WDT influences_VBZ the_DT production_NN of_IN protective_JJ borreliacidal_JJ antibody_NN ._SENT Borreliacidal_JJ antibody_NN was_VBD inhibited_VBN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN C3H/HeJ_NP mice_NNS vaccinated_VBN with_IN formalin-inactivated_JJ B._NP burgdorferi_NNS and_CC cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP and_CC treated_VBN with_IN recombinant_JJ gamma_NN interferon_NN (_( rIFN-gamma_NN )_) ._SENT The_DT suppression_NN of_IN production_NN of_IN outer_JJ surface_NN protein_NN A_NP (_( OspA_NP )_) borreliacidal_JJ antibody_NN by_IN rIFN-gamma_NNS was_VBD not_RB affected_VBN by_IN the_DT time_NN of_IN treatment_NN ._SENT In_IN addition_NN ,_, treatment_NN with_IN rIFN-gamma_NNS inhibited_VBD the_DT production_NN of_IN other_JJ anti-B_NN ._SENT burgdorferi_NN antibodies_NNS ._SENT By_IN contrast_NN ,_, treatment_NN of_IN cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS with_IN anti-IFN-gamma_NP marginally_RB increased_VBD the_DT production_NN of_IN borreliacidal_JJ antibody_NN and_CC enhanced_VBD the_DT production_NN of_IN other_JJ antibodies_NNS directed_VBN against_IN B._NP burgdorferi_NP ._SENT These_DT results_NNS show_VBP that_IN IFN-gamma_NP does_VBZ not_RB play_VB a_DT major_JJ role_NN in_IN the_DT production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN ._SENT Additional_JJ studies_NNS are_VBP needed_VBN to_TO determine_VB which_WDT cytokine(s)_NN will_MD enhance_VB production_NN of_IN borreliacidal_JJ antibody_NN ._SENT Public_JJ health_NN concerns_NNS about_IN the_DT morbidity_NN associated_VBN with_IN Lyme_NP borreliosis_NN have_VBP prompted_VBN the_DT development_NN of_IN several_JJ vaccines_NNS to_TO prevent_VB infection_NN with_IN Borrelia_NP burgdorferi_NP ._SENT The_DT efficacies_NNS of_IN the_DT vaccines_NNS are_VBP based_VBN on_IN the_DT ability_NN of_IN a_DT major_JJ outer_JJ surface_NN protein_NN (_( Osp_NP )_) of_IN B._NP burgdorferi_NP ,_, specifically_RB OspA_NP ,_, to_TO induce_VB antibody_NN that_WDT can_MD kill_VB the_DT Lyme_NP spirochete_NN in_IN vaccinees_NNS or_CC ticks_NNS ._SENT In_IN an_DT extensive_JJ field_NN trial_NN involving_VBG 10,936_CD participants_NNS ,_, the_DT vaccine_NN was_VBD 76_CD %_NN effective_JJ in_IN preventing_VBG infection_NN with_IN B._NP burgdorferi_NP after_IN three_CD inoculations_NNS ._SENT However_RB ,_, the_DT duration_NN of_IN protection_NN had_VBD not_RB been_VBN determined_VBN ._SENT In_IN addition_NN ,_, we_PP showed_VBD previously_RB that_IN vaccination_NN of_IN humans_NNS with_IN recombinant_JJ OspA_NP (_( rOspA_NP )_) induced_VBD only_RB low_JJ levels_NNS of_IN anti-OspA_NP borreliacidal_JJ antibody_NN and_CC that_IN the_DT borreliacidal_JJ response_NN waned_VBD rapidly_RB ._SENT Only_RB one_CD individual_NN had_VBD detectable_JJ anti-OspA_NN borreliacidal_JJ antibody_NN after_IN 180_CD days_NNS ._SENT A_DT similar_JJ anti-OspA_NN borreliacidal_JJ antibody_NN response_NN was_VBD detected_VBN in_IN hamsters_NNS vaccinated_VBN with_IN rOspA_NN ._SENT The_DT poor_JJ antibody_NN response_NN induced_VBN by_IN vaccination_NN may_MD have_VB contributed_VBN to_TO the_DT withdrawal_NN of_IN the_DT vaccine_NN ._SENT The_DT ability_NN of_IN rOspA_NN or_CC other_JJ protective_JJ immunogens_NNS to_TO induce_VB high_JJ and_CC sustained_JJ levels_NNS of_IN borreliacidal_JJ antibody_NN is_VBZ necessary_JJ to_TO ensure_VB prolonged_JJ protection_NN against_IN infection_NN with_IN B._NP burgdorferi_NP ._SENT Recently_RB ,_, we_PP developed_VBD an_DT in_IN vitro_NN system_NN to_TO determine_VB the_DT effects_NNS that_IN immunologic_JJ mediators_NNS have_VBP on_IN the_DT production_NN and_CC regulation_NN of_IN borreliacidal_JJ antibody_NN ._SENT Anti-OspA_NP borreliacidal_JJ antibody_NN was_VBD readily_RB produced_VBN when_WRB lymph_NN node_NN cells_NNS obtained_VBN from_IN vaccinated_VBN mice_NNS were_VBD cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT When_WRB OspA_NP borreliacidal_JJ antibody-producing_NN cells_NNS were_VBD exposed_VBN to_TO a_DT known_VBN B-lymphocyte-stimulating_NN factor_NN ,_, interleukin_NN 4_CD (_( IL-4_NN )_) ,_, borreliacidal-antibody_NN production_NN was_VBD inhibited_VBN ._SENT Furthermore_RB ,_, treatment_NN of_IN the_DT immune_JJ lymph_NN cell_NN cultures_NNS with_IN anti-murine_NN IL-4_NN did_VBD not_RB alter_VB the_DT production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN ._SENT These_DT results_NNS suggested_VBD that_IN IL-4_NN plays_VBZ a_DT minor_JJ role_NN in_IN the_DT production_NN and_CC up-regulation_NN of_IN borreliacidal_JJ antibody_NN ._SENT The_DT inability_NN of_IN IL-4-stimulated_JJ immune_JJ lymph_NN node_NN cells_NNS to_TO increase_VB production_NN of_IN borreliacidal_JJ antibody_NN may_MD be_VB due_JJ to_TO down-regulation_NN of_IN gamma_NN interferon_NN (_( IFN-gamma_NP )_) ._SENT It_PP is_VBZ known_VBN that_IN IL-4_NN strongly_RB down-regulates_VBZ functions_NNS promoted_VBN by_IN IFN-gamma_NP ,_, especially_RB class_NN switching_VBG to_TO immunoglobulin_NN G2a_NP (_( IgG2a_NP )_) by_IN B_NP lymphocytes_NNS ._SENT Since_IN B._NP burgdorferi_NP organisms_NNS are_VBP killed_VBN by_IN IgG2a_NP and_CC complement_VB ,_, we_PP sought_VBD evidence_NN of_IN whether_IN IFN-gamma_NP augments_VBZ anti-OspA_NN borreliacidal-antibody_NN production_NN ._SENT Such_JJ information_NN could_MD provide_VB insight_NN into_IN the_DT mechanism_NN of_IN borreliacidal-antibody_NN production_NN and_CC contribute_VB to_TO the_DT development_NN of_IN a_DT more_RBR efficacious_JJ Lyme_NP borreliosis_NN vaccine_NN ._SENT Mice_NNS ._SENT |_SYM Eight-_NN to_TO 12-week-old_JJ inbred_JJ C3H/HeJ_NP mice_NNS were_VBD obtained_VBN from_IN our_PP$ breeding_NN colony_NN located_VBN at_IN the_DT Wisconsin_NP State_NP Laboratory_NP of_IN Hygiene_NP ._SENT Mice_NNS weighing_VBG 20_CD to_TO 40_CD g_NN were_VBD housed_VBN four_CD per_IN cage_NN at_IN an_DT ambient_JJ temperature_NN of_IN 21C_JJ ._SENT Food_NN and_CC acidified_VBN water_NN were_VBD provided_VBN ad_NN libitum_NN ._SENT Organism_NN ._SENT |_SYM B._NP burgdorferi_NP sensu_NP stricto_NN isolate_NN 297_CD was_VBD originally_RB isolated_VBN from_IN human_JJ spinal_JJ fluid_NN ._SENT Low-passage_NP (_( <6_NN )_) organisms_NNS were_VBD cultured_VBN once_RB in_IN modified_JJ Barbour-Stoenner-Kelly_NP (_( BSK_NP )_) medium_NN containing_VBG screened_VBN lots_NNS of_IN bovine_JJ serum_NN albumin_NN to_TO a_DT concentration_NN of_IN 5_CD x_NN 107_CD spirochetes_NNS per_IN ml_NN ._SENT Five-hundred-microliter_NN samples_NNS were_VBD then_RB dispensed_VBN into_IN 1.5-ml_JJ screw-cap_NN tubes_NNS (_( Sarstedt_NP ,_, Newton_NP ,_, N.C._NP )_) containing_VBG 500_CD mul_NN of_IN BSK_NP supplemented_VBD with_IN 10_CD %_NN glycerol_NN (_( Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ,_, sealed_VBN ,_, and_CC stored_VBD at_IN -70C_NN ._SENT When_WRB necessary_JJ ,_, a_DT frozen_JJ suspension_NN of_IN spirochetes_NNS was_VBD thawed_VBN and_CC used_VBN to_TO inoculate_VB fresh_JJ BSK_NP medium_NN ._SENT The_DT spirochetes_NNS were_VBD viewed_VBN by_IN dark-field_JJ microscopy_NN and_CC enumerated_VBD using_VBG a_DT Petroff-Hausser_NP counting_NN chamber_NN ._SENT Preparation_NN of_IN vaccine_NN ._SENT |_SYM B._NP burgdorferi_NP organisms_NNS were_VBD grown_VBN in_IN 1_CD liter_NN of_IN BSK_NP medium_NN for_IN 6_CD days_NNS ,_, pelleted_VBN by_IN centrifugation_NN (_( 10,000_CD x_SYM g_NN ;_: 15C_NP ;_: 10_CD min_NN )_) ,_, and_CC washed_VBD three_CD times_NNS with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP ;_: pH_NN 7.4_CD )_) ._SENT The_DT washed_JJ pellet_NN was_VBD resuspended_VBN in_IN 1_CD %_NN formalin_NN ,_, incubated_VBN at_IN 32C_JJ for_IN 30_CD min_NN with_IN periodic_JJ mixing_VBG ,_, washed_VBD three_CD times_NNS by_IN centrifugation_NN with_IN PBS_NP (_( 12,000_CD x_SYM g_NN ;_: 10C_NP ;_: 15_CD min_NN )_) ,_, and_CC resuspended_JJ in_IN PBS_NP ._SENT Subsequently_RB ,_, the_DT formalin-inactivated_JJ spirochetes_NNS were_VBD mixed_VBN in_IN a_DT volume_NN of_IN a_DT 1_CD %_NN suspension_NN of_IN aluminum_NN hydroxide_NN (_( alum_NN ;_: Reheis_NP ,_, Berkeley_NP Heights_NP ,_, N.J._NP )_) to_TO yield_VB 4_CD x_SYM 106_CD spirochetes/ml_NN ._SENT Vaccination_NN of_IN mice_NNS ._SENT |_SYM We_PP showed_VBD previously_RB that_IN mice_NNS vaccinated_VBN with_IN whole_JJ cells_NNS of_IN B._NP burgdorferi_NNS with_IN or_CC without_IN alum_NN yielded_VBD higher_JJR levels_NNS of_IN anti-OspA_NP borreliacidal_JJ antibody_NN than_IN those_DT vaccinated_VBN with_IN rOspA_NN in_IN the_DT presence_NN or_CC absence_NN of_IN alum_NN ._SENT Therefore_RB ,_, whole_JJ cells_NNS of_IN B._NP burgdorferi_NP were_VBD used_VBN in_IN this_DT investigation_NN ._SENT Whole_JJ cells_NNS are_VBP not_RB recommended_VBN as_IN a_DT vaccine_NN for_IN human_JJ usage_NN ._SENT The_DT ability_NN of_IN whole_JJ cells_NNS to_TO consistently_RB induce_VB anti-OspA_NP borreliacidal_JJ antibody_NN in_IN mice_NNS permits_VBZ evaluation_NN of_IN cytokine_NN mechanisms_NNS responsible_JJ for_IN control_NN of_IN anti-OspA_NP borreliacidal_JJ ability_NN ._SENT Sixty_CD mice_NNS were_VBD mildly_RB anesthetized_VBN with_IN methoxyflurane_NN contained_VBN in_IN a_DT mouth-and-nose_JJ cup_NN and_CC vaccinated_VBD subcutaneously_RB in_IN the_DT inguinal_JJ region_NN with_IN 0.25_CD ml_NN (_( similar106B_NN ._SENT burgdorferi_NN organisms_NNS )_) of_IN the_DT formalin-inactivated_JJ vaccine_NN preparation_NN ._SENT The_DT suspension_NN contained_VBD approximately_RB 100_CD mug_NN of_IN borrelial_JJ protein_NN ._SENT Sham-vaccinated_JJ mice_NNS were_VBD injected_VBN with_IN BSK_NP medium_NN or_CC alum_NN alone_RB ._SENT Recovery_NN of_IN macrophages_NNS ._SENT |_SYM Five_NN to_TO 10_CD mice_NNS per_IN experimental_JJ protocol_NN were_VBD mildly_RB anesthetized_VBN with_IN methoxyflurane_NN contained_VBN in_IN a_DT mouth-and-nose_JJ cup_NN and_CC injected_VBD intraperitoneally_RB with_IN 2_CD ml_NN of_IN 3_CD %_NN 3-week-old_JJ thioglycolate_NN in_IN PBS_NP ._SENT Four_CD days_NNS after_IN injection_NN ,_, the_DT mice_NNS were_VBD euthanized_JJ by_IN CO2_NP asphyxiation_NN ,_, and_CC 8_CD ml_NN of_IN cold_JJ Hanks_NP '_POS balanced_JJ salt_NN solution_NN (_( Sigma_NP )_) was_VBD injected_VBN intraperitoneally_RB ._SENT The_DT peritoneal_JJ cavity_NN was_VBD massaged_VBN for_IN similar1_JJ min_NN ,_, and_CC the_DT exudate_NN cells_NNS were_VBD recovered_VBN by_IN aspiration_NN with_IN a_DT syringe_NN ._SENT The_DT suspension_NN of_IN peritoneal_JJ exudate_NN cells_NNS was_VBD centrifuged_VBN at_IN 1,500_CD rpm_NN (_( IEC_NP Centra-7_NP )_) for_IN 10_CD min_NN at_IN 4C_JJ ._SENT The_DT supernatant_JJ was_VBD decanted_VBN ,_, and_CC the_DT cells_NNS were_VBD resuspended_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( DMEM_NP ;_: Sigma_NP )_) that_WDT was_VBD free_JJ of_IN antimicrobial_JJ agents_NNS but_CC supplemented_VBN with_IN 10_CD %_NN heat-inactivated_VBN (_( 56C_NP ;_: 45_CD min_NN )_) fetal_JJ bovine_JJ serum_NN (_( HyClone_NP Laboratories_NP ,_, Logan_NP ,_, Utah_NP )_) ,_, 5_CD x_SYM 10-5_CD M_NP 2-mercaptoethanol_NP (_( Sigma_NP )_) ,_, and_CC l-glutamine_JJ (_( 2.92_CD mg/ml_NN ;_: Sigma_NP )_) ._SENT Aliquots_NNS of_IN the_DT cell_NN suspension_NN were_VBD then_RB poured_VBN over_IN polystyrene_NN tissue_NN culture_NN dishes_NNS (_( 100_CD by_IN 20_CD mm_NN ;_: Corning_NP Glass_NP Works_NP ,_, Corning_NP ,_, N.Y._NP )_) and_CC incubated_VBN at_IN 37C_JJ in_IN a_DT humidified_VBN atmosphere_NN of_IN 5.0_CD %_NN CO2_NN for_IN 4_CD to_TO 6_CD h._NN After_IN incubation_NN ,_, the_DT nonadherent_JJ cells_NNS were_VBD aspirated_VBN from_IN the_DT tissue_NN culture_NN dishes_NNS ._SENT The_DT dishes_NNS were_VBD gently_RB rinsed_VBN twice_RB with_IN 8-ml_JJ portions_NNS of_IN warm_JJ Hanks_NP '_POS balanced_JJ salt_NN solution_NN to_TO further_RBR eliminate_VB nonadherent_JJ cells_NNS ._SENT Five_CD milliliters_NNS of_IN cold_JJ ,_, nonenzymatic_JJ cell_NN lifter_NN (_( Sigma_NP )_) was_VBD then_RB added_VBN to_TO each_DT tissue_NN culture_NN dish_NN and_CC incubated_VBN at_IN 4C_JJ for_IN 30_CD min_NN ._SENT The_DT macrophages_NNS were_VBD detached_VBN from_IN the_DT surfaces_NNS of_IN the_DT dishes_NNS by_IN vigorously_RB tapping_VBG and_CC gently_RB scraping_VBG the_DT inside_NN of_IN the_DT tissue_NN culture_NN dishes_NNS with_IN a_DT sterile_JJ rubber_NN policeman_NN ._SENT Suspensions_NNS of_IN macrophages_NNS from_IN several_JJ tissue_NN culture_NN dishes_NNS were_VBD aspirated_VBN ,_, pooled_VBN ,_, and_CC centrifuged_VBD at_IN 1,500_CD rpm_NN for_IN 10_CD min_NN at_IN 4C_JJ ._SENT The_DT supernatant_JJ was_VBD decanted_VBN ,_, and_CC the_DT pellet_NN was_VBD resuspended_VBN in_IN 1_CD ml_NN of_IN DMEM_NP ._SENT Cell_NN viability_NN was_VBD determined_VBN by_IN trypan_JJ blue_JJ exclusion_NN ._SENT The_DT preparations_NNS of_IN macrophages_NNS obtained_VBN by_IN this_DT method_NN were_VBD 98_CD %_NN free_JJ of_IN lymphocyte_NN contamination_NN ._SENT Isolation_NN of_IN lymph_NN node_NN cells_NNS ._SENT |_SYM Mice_NN were_VBD euthanized_JJ by_IN CO2_NP inhalation_NN 17_CD days_NNS after_IN vaccination_NN with_IN formalin-inactivated_JJ B._NP burgdorferi_NNS ._SENT The_DT inguinal_JJ lymph_NN nodes_NNS were_VBD removed_VBN from_IN vaccinated_VBN and_CC nonvaccinated_JJ mice_NNS and_CC placed_VBN in_IN cold_JJ DMEM_NP ._SENT Single-cell_NN suspensions_NNS of_IN lymph_NN node_NN cells_NNS were_VBD prepared_VBN by_IN teasing_VBG apart_RP the_DT lymph_NN nodes_NNS with_IN forceps_NN and_CC gently_RB pressing_VBG them_PP through_IN a_DT sterile_JJ stainless_JJ steel_NN 60-mesh_JJ screen_NN into_IN antimicrobial-free_JJ cold_JJ DMEM_NN supplemented_VBN with_IN 10_CD %_NN heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN ,_, l-glutamine_NN ,_, and_CC 2-mercaptoethanol_JJ ._SENT The_DT lymph_NN node_NN cells_NNS were_VBD washed_VBN twice_RB by_IN centrifugation_NN (_( 1,500_CD rpm_NN ;_: 4C_NP ;_: 10_CD min_NN )_) with_IN DMEM_NP ._SENT The_DT supernatants_NNS were_VBD decanted_VBN ,_, and_CC the_DT pellets_NNS were_VBD resuspended_VBN in_IN 1_CD ml_NN of_IN cold_JJ DMEM_NP ._SENT Cell_NN viability_NN was_VBD assessed_VBN by_IN trypan_JJ blue_JJ exclusion_NN ._SENT Production_NN of_IN antibody_NN in_IN vitro_NN ._SENT |_SYM Sterile_NP six-well_NP flat-bottom_NN tissue_NN culture_NN dishes_NNS (_( Becton_NP Dickinson_NP ,_, Lincoln_NP Park_NP ,_, N.J._NP )_) were_VBD inoculated_VBN with_IN lymph_NN node_NN cells_NNS (_( 5_CD x_SYM 106_LS )_) obtained_VBN from_IN vaccinated_VBN or_CC nonvaccinated_JJ mice_NNS ,_, macrophages_NNS (_( 105_CD )_) ,_, and_CC 106_CD live_JJ B._NP burgdorferi_NN organisms_NNS ._SENT DMEM_NP was_VBD added_VBN to_TO the_DT suspensions_NNS of_IN cells_NNS to_TO bring_VB the_DT final_JJ volume_NN to_TO 3_CD ml_NN ._SENT On_IN days_NNS 3_CD ,_, 6_CD ,_, 9_CD ,_, 12_CD ,_, and_CC 15_CD after_IN cultivation_NN at_IN 37C_JJ in_IN the_DT presence_NN of_IN 5.0_CD %_NN CO2_NP ,_, 1.0-ml_JJ samples_NNS of_IN the_DT supernatants_NNS were_VBD removed_VBN after_IN gentle_JJ agitation_NN and_CC replaced_VBN with_IN equal_JJ volumes_NNS of_IN warm_JJ DMEM_NP ._SENT In_IN some_DT experiments_NNS ,_, rIFN-gamma_NNS at_IN quantities_NNS ranging_VBG from_IN 0.1_CD to_TO 10_CD mug_NN or_CC rat_NN anti-murine_NN IFN-gamma_NP at_IN quantities_NNS ranging_VBG from_IN 25_CD to_TO 75_CD mug_NN (_( R&D_NP Systems_NP ,_, Minneapolis_NP ,_, Minn._NP )_) was_VBD added_VBN to_TO cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS ,_, macrophages_NNS ,_, and_CC B._NP burgdorferi_NP at_IN 10_CD min_NN and_CC 2_CD and_CC 4_CD days_NNS of_IN incubation_NN ._SENT In_IN other_JJ experiments_NNS ,_, rat_NN anti-murine_NN CD119_NN at_IN quantities_NNS ranging_VBG from_IN 1_CD to_TO 100_CD mug_NN (_( PharMingen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) was_VBD added_VBN to_TO cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS ,_, macrophages_NNS ,_, and_CC B._NP burgdorferi_NP at_IN 10_CD min_NN of_IN incubation_NN ._SENT In_IN similar_JJ fashion_NN ,_, control_NN cultures_NNS were_VBD treated_VBN with_IN a_DT rat_NN isotype-nonspecific_JJ antibody_NN ._SENT Supernatants_NNS were_VBD collected_VBN after_IN centrifugation_NN at_IN 13,000_CD rpm_NN for_IN 8_CD min_NN to_TO remove_VB spirochetes_NNS and_CC other_JJ cellular_JJ debris_NN ._SENT Supernatants_NNS were_VBD stored_VBN at_IN -70C_NN until_IN they_PP were_VBD used_VBN ._SENT Detection_NN of_IN borreliacidal_JJ antibody_NN by_IN membrane_NN filtration_NN ._SENT |_SYM The_DT frozen_JJ supernatants_NNS were_VBD thawed_VBN ,_, heat_NN inactivated_VBN (_( 56C_NP ,_, 30_CD min_NN )_) ,_, sterilized_VBN with_IN a_DT 0.22-mum-pore-size_JJ filter_NN (_( Acrodisk_NP ;_: Gelman_NP Sciences_NPS ,_, Ann_NP Arbor_NP ,_, Mich._NP )_) ,_, and_CC serially_RB twofold_RB diluted_JJ (_( from_IN undiluted_JJ to_TO 1:8,192_CD )_) with_IN fresh_JJ BSK_NP medium_NN ._SENT One_CD hundred-microliter_NN aliquots_NNS of_IN each_DT dilution_NN were_VBD transferred_VBN to_TO 1.5-ml_JJ screw-cap_NN tubes_NNS (_( Sarstedt_NP )_) ,_, and_CC 100_CD mul_NN of_IN BSK_NP containing_VBG 104B_JJ ._SENT burgdorferi_NN organisms_NNS per_IN ml_NN was_VBD added_VBN along_RP with_IN 20_CD mul_NN of_IN sterile_JJ guinea_NN pig_NN complement_NN (_( Sigma_NP )_) ._SENT The_DT tubes_NNS were_VBD then_RB gently_RB shaken_VBN and_CC incubated_VBN for_IN 3_CD days_NNS at_IN 32C_JJ ._SENT Controls_NNS included_VBD filter-sterilized_JJ supernatants_NNS obtained_VBN from_IN suspensions_NNS of_IN nonimmune_JJ lymph_NN node_NN cells_NNS with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT Other_JJ controls_NNS included_VBD supernatants_NNS from_IN nonimmune_JJ lymph_NN node_NN cells_NNS ,_, macrophages_NNS alone_RB ,_, and_CC DMEM_NP ._SENT After_IN incubation_NN ,_, 100_CD mul_NN of_IN each_DT suspension_NN was_VBD removed_VBN and_CC placed_VBN in_IN individual_JJ 1.5-ml_JJ screw-cap_NN tubes_NNS (_( Sarstedt_NP )_) ._SENT Subsequently_RB ,_, 100_CD mul_NN of_IN a_DT solution_NN of_IN propidium_NN iodide_NN (_( 1.0_CD mg/ml_NN ;_: Molecular_NP Probes_NP ,_, Eugene_NP ,_, Oreg_NP ._SENT )_) diluted_VBD 1:20_CD in_IN sterile_JJ PBS_NP was_VBD added_VBN ._SENT The_DT suspensions_NNS were_VBD briefly_RB mixed_VBN before_IN being_VBG incubated_VBN at_IN 56C_NN for_IN 30_CD min_NN to_TO permit_VB intercalation_NN of_IN propidium_NN iodide_NN into_IN the_DT spirochetes_NNS ._SENT One_CD hundred_CD microliters_NNS of_IN each_DT sample_NN was_VBD then_RB filtered_VBN through_IN 0.22-mum-pore-size_JJ Nuclepore_NP polycarbonate_JJ membrane_NN filters_NNS (_( 47-mm_JJ diameter_NN ;_: Whatman_NP Nuclepore_NP ,_, Clifton_NP ,_, N.J._NP )_) under_IN negative_JJ pressure_NN with_IN a_DT single-place_NN sterility_NN test_NN manifold_NN (_( Millipore_NP Corporation_NP ,_, Bedford_NP ,_, Mass._NP )_) attached_VBD to_TO a_DT vacuum_NN pump_NN ._SENT The_DT membrane_NN filters_NNS were_VBD washed_VBN with_IN similar8_JJ ml_NN of_IN sterile_JJ double-distilled_JJ H2O_NP (_( ddH2O_NP )_) ,_, removed_VBN from_IN the_DT vacuum_NN apparatus_NN ,_, allowed_VBN to_TO dry_VB ,_, and_CC placed_VBN onto_IN glass_NN microscope_NN slides_NNS ._SENT Coverslips_NNS were_VBD placed_VBN on_IN the_DT filters_NNS before_IN they_PP were_VBD viewed_VBN with_IN a_DT Laborlux_NP S_NP fluorescence_NN microscope_NN (_( Leitz_NP ,_, Wetzlar_NP ,_, Germany_NP )_) using_VBG an_DT x50_JJ oil_NN immersion_NN objective_NN ._SENT The_DT number_NN of_IN spirochetes_NNS on_IN each_DT filter_NN was_VBD determined_VBN by_IN viewing_VBG similar30_JJ fields_NNS ._SENT The_DT borreliacidal-antibody_NN titer_NN was_VBD defined_VBN as_IN the_DT reciprocal_NN of_IN the_DT dilution_NN preceding_VBG the_DT dilution_NN at_IN which_WDT the_DT number_NN of_IN spirochetes_NNS or_CC clumping_VBG was_VBD equal_JJ to_TO that_DT of_IN the_DT control_NN ._SENT Generally_RB ,_, individual_JJ spirochetes_NNS with_IN a_DT few_JJ clumps_NNS were_VBD uniformly_RB distributed_VBN throughout_IN the_DT fields_NNS on_IN filters_NNS of_IN the_DT control_NN supernatants_NNS ._SENT Western_JJ immunoblotting_NN ._SENT |_SYM B._NP burgdorferi_NNS 297_CD organisms_NNS were_VBD grown_VBN in_IN 1_CD liter_NN of_IN BSK_NP medium_NN for_IN 6_CD days_NNS ,_, pelleted_VBN by_IN centrifugation_NN (_( 10,000_CD x_SYM g_NN ;_: 15C_NP ;_: 10_CD min_NN )_) ,_, and_CC washed_VBD three_CD times_NNS with_IN PBS_NP at_IN pH_NN 7.4_CD ._SENT The_DT washed_JJ pellet_NN was_VBD resuspended_VBN in_IN 1_CD %_NN formalin_NN and_CC incubated_VBN at_IN 32C_JJ for_IN 30_CD min_NN with_IN periodic_JJ mixing_VBG and_CC then_RB washed_VBN three_CD times_NNS by_IN centrifugation_NN with_IN PBS_NP (_( 12,000_CD x_SYM g_NN ;_: 10C_NP ;_: 15_CD min_NN )_) and_CC resuspended_JJ in_IN PBS_NP ._SENT The_DT spirochetes_NNS were_VBD suspended_VBN in_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN sample_NN buffer_NN and_CC boiled_VBD for_IN similar3_JJ min_NN ._SENT One_CD hundred_CD twenty_CD micrograms_NNS of_IN B._NP burgdorferi_NP lysate_NNS was_VBD loaded_VBN onto_IN a_DT preparative_JJ 12_CD %_NN acrylamide_NN gel_NN ,_, and_CC the_DT proteins_NNS were_VBD resolved_VBN by_IN overnight_JJ electrophoresis_NN at_IN similar7_JJ mA_NNS constant_JJ current_NN with_IN the_DT buffer_NN system_NN of_IN Laemmli_NP ._SENT The_DT proteins_NNS were_VBD transferred_VBN onto_IN a_DT nitrocellulose_NN membrane_NN for_IN 1_CD h_NN at_IN 20_CD V_CD ,_, using_VBG a_DT semidry_NN blotting_VBG apparatus_NN (_( Bio-Rad_NP Laboratories_NP ,_, Hercules_NP ,_, Calif._NP )_) ._SENT The_DT nitrocellulose_NN membrane_NN was_VBD incubated_VBN overnight_RB at_IN 4C_JJ in_IN 5_CD %_NN milk_NN dissolved_VBN in_IN Tris-buffered_JJ saline_NN with_IN 0.05_CD %_NN Tween_NP 20_CD (_( TBS-T_NP ;_: pH_NN 7.4_CD )_) to_TO block_VB nonspecific_JJ reactivity_NN ,_, washed_VBD two_CD times_NNS each_DT with_IN TBS-T_NP and_CC ddH2O_NP ,_, allowed_VBD to_TO dry_VB ,_, and_CC finally_RB cut_VBN into_IN strips_NNS ._SENT The_DT strips_NNS were_VBD washed_VBN three_CD times_NNS with_IN TBS_NP and_CC subsequently_RB incubated_VBN for_IN 1_CD h_NN with_IN a_DT 1:1,000_CD dilution_NN of_IN an_DT alkaline_JJ phosphatase-conjugated_JJ goat_NN anti-murine_NN IgG_NP (_( heavy_JJ and_CC light_JJ chain_NN specific_NN ;_: Kirkegaard_NP &_CC Perry_NP Laboratories_NPS ,_, Gaithersburg_NP ,_, Md._NP )_) in_IN 5_CD %_NN milk_NN in_IN TBS-T_NP ._SENT This_DT was_VBD followed_VBN by_IN four_CD washes_VBZ with_IN TBS_NP ._SENT The_DT strips_NNS were_VBD developed_VBN by_IN the_DT addition_NN of_IN 5-bromo-4-chloro-3-indolylphosphate-nitroblue_JJ tetrazolium_NN substrate_NN (_( Kirkegaard_NP &_CC Perry_NP )_) ._SENT The_DT reactions_NNS were_VBD stopped_VBN after_IN 2_CD min_NN with_IN several_JJ large_JJ volumes_NNS of_IN chilled_VBN ddH2O_NN ._SENT Flow_NN cytometric_JJ analysis_NN of_IN immune_JJ supernatants_NNS ._SENT |_SYM Suspensions_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS containing_VBG macrophages_NNS and_CC B._NP burgdorferi_NP in_IN the_DT presence_NN or_CC absence_NN of_IN IFN-gamma_NP ,_, anti-IFN-gamma_NP ,_, or_CC isotype-nonspecific_JJ antibody_NN were_VBD analyzed_VBN for_IN the_DT numbers_NNS of_IN cells_NNS ,_, B_NP lymphocytes_NNS ,_, and_CC T_NN lymphocytes_NNS on_IN day_NN 4_CD of_IN incubation_NN by_IN using_VBG flow_NN cytometry_NN ._SENT Briefly_RB ,_, suspensions_NNS (_( 1_CD ml_NN )_) of_IN immune_JJ lymph_NN node_NN cells_NNS were_VBD placed_VBN in_IN chilled_VBN centrifuge_NN tubes_NNS ,_, and_CC the_DT total_JJ number_NN of_IN lymphocytes_NNS was_VBD determined_VBN ._SENT The_DT suspensions_NNS of_IN cells_NNS were_VBD then_RB mixed_VBN with_IN both_DT phycoerythrin-conjugated_JJ anti-murine_NN CD3_NP (_( 5_CD mul_NN of_IN a_DT 1:5_CD dilution_NN ;_: PharMingen_NP )_) and_CC fluorescein_NN isothiocyanate-conjugated_VBN anti-murine_NP CD45R/B220_NP (_( 10_CD mul_NN of_IN a_DT 1:50_CD dilution_NN ;_: PharMingen_NP )_) and_CC incubated_VBN at_IN 4C_JJ for_IN 15_CD min_NN ._SENT The_DT cells_NNS were_VBD washed_VBN twice_RB by_IN centrifugation_NN with_IN PBS_NP containing_VBG 0.1_CD %_NN bovine_JJ serum_NN albumin_NN (_( 1,500_CD rpm_NN ;_: 4C_NP ;_: 10_CD min_NN )_) ._SENT The_DT pellets_NNS of_IN cells_NNS were_VBD resuspended_VBN in_IN 250_CD mul_NN of_IN cold_JJ DMEM_NP and_CC kept_VBD in_IN the_DT dark_NN at_IN 4C_JJ until_IN they_PP were_VBD analyzed_VBN by_IN flow_NN cytometry_NN ._SENT One_CD hundred_CD microliters_NNS of_IN 50-mug/ml_JJ propidium_NN iodide_NN (_( Sigma_NP )_) was_VBD then_RB added_VBN to_TO each_DT tube_NN just_RB prior_RB to_TO acquisition_NN by_IN the_DT flow_NN cytometer_NN to_TO discriminate_VB viable_JJ and_CC nonviable_JJ cells_NNS ._SENT Data_NNS were_VBD acquired_VBN on_IN a_DT FACSCalibur_NP flow_NN cytometer_NN (_( Becton_NP Dickinson_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) using_VBG CellQuest_NP acquisition_NN and_CC analysis_NN software_NN (_( Becton_NP Dickinson_NP )_) ._SENT Twenty_CD thousand_CD events_NNS were_VBD detected_VBN by_IN forward_JJ and_CC side_JJ angle_NN light_NN scatter_NN and_CC by_IN propidium_NN iodide_NN ,_, phycoerythrin_NN ,_, and_CC fluorescein_NN isothiocyanate_NN fluorescence_NN ._SENT A_DT dot_NN blot_NN profile_NN of_IN forward_JJ angle_NN light_NN scatter_NN and_CC propidium_NN iodide_NN fluorescence_NN enabled_VBD identification_NN and_CC gating_VBG of_IN live_JJ lymphocyte_NN populations_NNS ._SENT The_DT gated_VBN events_NNS were_VBD subsequently_RB analyzed_VBN by_IN quadrant_NN dot_VBP blots_NNS of_IN phycoerythrin_NN and_CC fluorescein_NN isothiocyanate_NN fluorescence_NN for_IN enumeration_NN of_IN CD3+_NP and_CC B220+_NP lymphocytes_NNS in_IN a_DT given_VBN sample_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM A_DT t_NN test_NN was_VBD used_VBN to_TO determine_VB significant_JJ differences_NNS in_IN the_DT titers_NNS of_IN borreliacidal_JJ antibody_NN and_CC in_IN lymphocyte_NN counts_NNS among_IN supernatants_NNS ._SENT In_IN addition_NN ,_, titers_NNS that_WDT were_VBD determined_VBN during_IN kinetic_JJ studies_NNS of_IN in_IN vitro_NN borreliacidal_JJ antibody_NN production_NN were_VBD tested_VBN by_IN analysis_NN of_IN variance_NN ,_, utilizing_VBG the_DT Minitab_NP statistical_JJ analysis_NN program_NN ._SENT The_DT Fisher_NP least-significant-difference_NN test_NN was_VBD used_VBN to_TO examine_VB pairs_NNS of_IN means_NNS when_WRB a_DT significant_JJ F_NN ratio_NN indicated_VBD reliable_JJ mean_JJ differences_NNS ._SENT The_DT alpha_NN level_NN was_VBD set_VBN at_IN 0.05_CD before_IN the_DT experiments_NNS were_VBD started_VBN ._SENT Modulation_NN of_IN in_IN vitro_NN production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN by_IN IFN-gamma_NP ._SENT |_SYM We_PP showed_VBD previously_RB that_IN anti-OspA_NP borreliacidal_JJ antibody_NN is_VBZ readily_RB detected_VBN in_IN supernatants_NNS of_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN mice_NNS vaccinated_VBN with_IN formalin-treated_JJ B._NP burgdorferi_NNS in_IN adjuvant_JJ and_CC cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NNS for_IN several_JJ days_NNS ._SENT The_DT data_NNS presented_VBN in_IN Fig._NN confirms_VBZ and_CC extends_VBZ these_DT findings_NNS ._SENT High_JJ levels_NNS of_IN anti-OspA_NP borreliacidal_JJ antibody_NN (_( titer_NN ,_, 256_CD )_) were_VBD detected_VBN in_IN supernatants_NNS on_IN day_NN 6_CD of_IN culture_NN of_IN immune_JJ lymph_NN node_NN cells_NNS with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT The_DT peak_NN anti-OspA_NN borreliacidal_JJ activity_NN (_( titer_NN ,_, 1,024_CD )_) was_VBD detected_VBN with_IN supernatants_NNS obtained_VBN on_IN days_NNS 9_CD to_TO 15_CD of_IN culture_NN ._SENT When_WRB cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS with_IN macrophages_NNS and_CC B._NP burgdorferi_NP were_VBD exposed_VBN to_TO 0.1_CD ,_, 1.0_CD ,_, or_CC 10_CD mug_NN of_IN rIFN-gamma_NN ,_, the_DT levels_NNS of_IN anti-OspA_NP borreliacidal_JJ antibody_NN were_VBD significantly_RB reduced_VBN 16-fold_NN or_CC more_JJR ._SENT Maximum_JJ suppression_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN occurred_VBN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS exposed_VBN to_TO 0.1_CD mug_NN of_IN rIFN-gamma_NNS followed_VBN by_IN 1.0_CD and_CC 10_CD mug_NN of_IN rIFN-gamma_NNS ._SENT The_DT borreliacidal_JJ activity_NN was_VBD due_JJ to_TO the_DT production_NN of_IN anti-OspA_NN antibody_NN ._SENT Adsorption_NN of_IN the_DT supernatant_JJ from_IN immune_JJ lymph_NN node_NN cells_NNS with_IN rOspA_NP reduced_VBD the_DT borreliacidal-antibody_NN titer_NN ._SENT No_DT borreliacidal_JJ antibody_NN was_VBD detected_VBN in_IN supernatants_NNS obtained_VBN from_IN nonimmune_JJ lymph_NN node_NN cells_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT When_WRB these_DT studies_NNS were_VBD repeated_VBN three_CD times_NNS ,_, similar_JJ results_NNS were_VBD obtained_VBN ._SENT In_IN other_JJ studies_NNS ,_, immune_JJ lymph_NN node_NN cells_NNS were_VBD treated_VBN with_IN 25_CD ,_, 50_CD ,_, or_CC 75_CD mug_NN of_IN anti-murine_NP IFN-gamma_NP ._SENT Anti-OspA_NP borreliacidal-antibody_NN production_NN was_VBD increased_VBN two-_NN to_TO fourfold_JJ in_IN supernatants_NNS obtained_VBN from_IN immune_JJ lymph_NN node_NN cell_NN cultures_NNS treated_VBN with_IN 50_CD or_CC 75_CD mug_NN of_IN anti-IFN-gamma_NN for_IN 9_CD days_NNS or_CC more_RBR compared_VBN to_TO the_DT levels_NNS of_IN anti-OspA_NP borreliacidal_JJ antibody_NN detected_VBN in_IN cultures_NNS of_IN untreated_JJ immune_JJ lymph_NN node_NN cells_NNS ._SENT However_RB ,_, treatment_NN of_IN immune_JJ lymph_NN node_NN cells_NNS with_IN 25_CD mug_NN of_IN anti-IFN-gamma_NP did_VBD not_RB affect_VB the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT No_DT borreliacidal_JJ antibody_NN was_VBD detected_VBN in_IN supernatants_NNS obtained_VBN from_IN nonimmune_JJ lymph_NN node_NN cells_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT Similar_JJ results_NNS were_VBD obtained_VBN when_WRB these_DT studies_NNS were_VBD repeated_VBN ._SENT Temporal_JJ effects_NNS of_IN rIFN-gamma_NNS and_CC anti-IFN-gamma_NNS on_IN the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT |_SYM Immune_NP lymph_NN node_NN cell_NN cultures_NNS were_VBD treated_VBN with_IN rIFN-gamma_NNS or_CC anti-IFN-gamma_NNS at_IN 10_CD min_NN or_CC 2_CD or_CC 4_CD days_NNS after_IN cultivation_NN ._SENT Production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN was_VBD inhibited_VBN by_IN rIFN-gamma_NNS at_IN all_DT treatment_NN intervals_NNS ,_, although_IN less_JJR effect_NN was_VBD detected_VBN with_IN rIFN-gamma_NN treatment_NN on_IN day_NN 4_CD of_IN cultivation_NN ._SENT Treatment_NN of_IN immune_JJ lymph_NN node_NN cell_NN cultures_NNS with_IN anti-IFN-gamma_NNS slightly_RB enhanced_VBN production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN at_IN all_DT treatment_NN intervals_NNS ._SENT When_WRB these_DT studies_NNS were_VBD repeated_VBN ,_, similar_JJ results_NNS were_VBD obtained_VBN ._SENT Effects_NNS of_IN rIFN-gamma_NNS and_CC anti-IFN-gamma_NNS on_IN production_NN of_IN anti-B_NN ._SENT burgdorferi_NN antibody_NN ._SENT |_SYM Figure_NN shows_VBZ that_DT supernatant_JJ obtained_VBN from_IN immune_JJ lymph_NN node_NN cells_NNS (_( day_NN 17_CD after_IN vaccination_NN )_) cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP for_IN 9_CD days_NNS produced_VBD predominately_RB anti-OspA_NP (_( 31-kDa_NP )_) antibody_NN ._SENT Treatment_NN of_IN the_DT lymph_NN node_NN cell_NN cultures_NNS with_IN rIFN-gamma_NNS abrogated_VBD the_DT antibody_NN response_NN ._SENT By_IN contrast_NN ,_, treatment_NN of_IN immune_JJ lymph_NN node_NN cell_NN cultures_NNS with_IN anti-IFN-gamma_NP induced_VBD production_NN of_IN antibodies_NNS to_TO multiple_JJ B._NP burgdorferi_NN antigens_NNS ._SENT Furthermore_RB ,_, supernatant_JJ from_IN anti-IFN-gamma-treated_JJ lymph_NN node_NN cell_NN cultures_NNS had_VBD an_DT anti-OspA_NP Western_NP immunoblot_NN titer_NN of_IN 40,960_CD compared_VBN to_TO a_DT titer_NN of_IN 2,560_CD for_IN supernatant_JJ obtained_VBN from_IN untreated_JJ immune_JJ lymph_NN node_NN cell_NN cultures_NNS ._SENT Flow_NN cytometric_JJ analysis_NN of_IN lymph_NN node_NN cell_NN cultures_NNS ._SENT |_SYM Immune_NP lymph_NN node_NN cells_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP in_IN the_DT presence_NN or_CC absence_NN of_IN rIFN-gamma_NNS or_CC anti-IFN-gamma_NNS for_IN 4_CD days_NNS were_VBD analyzed_VBN for_IN viability_NN and_CC numbers_NNS of_IN T_NN and_CC B_NN lymphocytes_NNS by_IN using_VBG flow_NN cytometry_NN ._SENT Figure_NN shows_VBZ that_IN the_DT number_NN of_IN viable_JJ cells_NNS in_IN lymph_NN node_NN cell_NN cultures_NNS treated_VBN with_IN rIFN-gamma_NNS decreased_VBD approximately_RB 25_CD %_NN from_IN the_DT number_NN of_IN viable_JJ cells_NNS detected_VBN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS treated_VBN with_IN an_DT isotype-nonspecific_JJ antibody_NN or_CC anti-IFN-gamma_NN ._SENT In_IN addition_NN ,_, the_DT number_NN of_IN B_NP lymphocytes_NNS (_( B220_NP marker_NN )_) decreased_VBD approximately_RB 50_CD %_NN in_IN lymph_NN node_NN cell_NN cultures_NNS treated_VBN with_IN rIFN-gamma_NNS compared_VBN to_TO the_DT control_NN ._SENT By_IN contrast_NN ,_, a_DT 10_CD %_NN increase_NN in_IN B_NP lymphocytes_NNS was_VBD detected_VBN in_IN lymph_NN node_NN cell_NN cultures_NNS treated_VBN with_IN anti-IFN-gamma_NP ._SENT Similarly_RB ,_, the_DT number_NN of_IN T_NN lymphocytes_NNS (_( CD3_NP marker_NN )_) decreased_VBD approximately_RB 25_CD %_NN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS treated_VBN with_IN rIFN-gamma_NNS ,_, while_IN a_DT 6_CD %_NN decrease_NN was_VBD detected_VBN in_IN cultures_NNS treated_VBN with_IN anti-IFN-gamma_NNS compared_VBN to_TO control_VB cultures_NNS ._SENT When_WRB these_DT studies_NNS were_VBD repeated_VBN ,_, similar_JJ results_NNS were_VBD obtained_VBN ._SENT Effect_NN of_IN rIFN-gamma_NNS on_IN macrophages_NNS ._SENT |_SYM In_IN other_JJ studies_NNS ,_, the_DT lymph_NN node_NN cell_NN cultures_NNS treated_VBN with_IN an_DT isotype-nonspecific_JJ antibody_NN (_( control_NN )_) ,_, rIFN-gamma_NP ,_, or_CC anti-IFN-gamma_NP were_VBD gently_RB washed_VBN to_TO remove_VB nonadherent_JJ cells_NNS and_CC viewed_VBN by_IN light_JJ microscopy_NN ._SENT The_DT macrophages_NNS cultured_VBN with_IN rIFN-gamma_NNS were_VBD rounded_VBN and_CC lacked_VBN pseudopodia_NNS ,_, whereas_IN macrophages_NNS treated_VBN with_IN the_DT isotype-nonspecific_JJ antibody_NN or_CC anti-IFN-gamma_NN were_VBD spindle_NN shaped_VBN with_IN long_JJ pseudopodia_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Effect_NN of_IN 0.1_CD ,_, 1_CD ,_, or_CC 10_CD mug_NN (_( *_SYM )_) of_IN rIFN-gamma_NNS on_IN production_NN of_IN borreliacidal_JJ antibody_NN by_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN 17-day-vaccinated_JJ mice_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP Effect_NP of_IN 0.1_CD ,_, 1_CD ,_, or_CC 10_CD mug_NN (_( *_SYM )_) of_IN rIFN-gamma_NNS on_IN production_NN of_IN borreliacidal_JJ antibody_NN by_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN 17-day-vaccinated_JJ mice_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP for_IN 3_CD ,_, 6_CD ,_, 9_CD ,_, 12_CD ,_, and_CC 15_CD days_NNS ._SENT Controls_NNS included_VBD lymph_NN node_NN cells_NNS obtained_VBN from_IN vaccinated_VBN and_CC nonvaccinated_JJ mice_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT The_DT error_NN bars_NNS indicate_VBP standard_JJ deviations_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Effect_NN of_IN 25_CD ,_, 50_CD ,_, or_CC 75_CD mug_NN (_( *_SYM )_) of_IN anti-IFN-gamma_NN on_IN production_NN of_IN borreliacidal_JJ antibody_NN by_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN 17-day-vaccinated_JJ mice_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP Effect_NP of_IN 25_CD ,_, 50_CD ,_, or_CC 75_CD mug_NN (_( *_SYM )_) of_IN anti-IFN-gamma_NN on_IN production_NN of_IN borreliacidal_JJ antibody_NN by_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN 17-day-vaccinated_JJ mice_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP for_IN 3_CD ,_, 6_CD ,_, 9_CD ,_, 12_CD ,_, and_CC 15_CD days_NNS ._SENT Controls_NNS included_VBD lymph_NN node_NN cells_NNS obtained_VBN from_IN vaccinated_VBN and_CC nonvaccinated_JJ mice_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP ._SENT The_DT error_NN bars_NNS indicate_VBP standard_JJ deviations_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Borreliacidal-antibody_NP response_NN of_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN 17-day-vaccinated_JJ mice_NNS cultured_VBN with_IN B._NP burgdorferi_NP Borreliacidal-antibody_NP response_NN of_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN 17-day-vaccinated_JJ mice_NNS cultured_VBN with_IN B._NP burgdorferi_NNS and_CC macrophages_NNS and_CC treated_VBN with_IN rIFN-gamma_NP (_( A_NP )_) or_CC anti-IFN-gamma_NP (_( B_NP )_) 10_CD min_NN (_( large-grid_JJ bars_NNS )_) or_CC 2_CD (_( small-grid_NN bars_NNS )_) or_CC 4_CD (_( cross-hatched_JJ bars_NNS )_) days_NNS after_IN cultivation_NN ._SENT Control_NN cultures_NNS (_( solid_JJ bars_NNS )_) were_VBD treated_VBN with_IN PBS_NP (_( A_NP )_) or_CC an_DT isotype-nonspecific_JJ antibody_NN (_( B_NP )_) ._SENT The_DT error_NN bars_NNS indicate_VBP standard_JJ deviations_NNS ._SENT FIG._NN 4_CD ._SENT |_SYM Western_JJ immunoblots_NNS obtained_VBN with_IN supernatants_NNS from_IN cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS (_( day_NN 17_CD after_IN vaccination_NN )_) cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP Western_NP immunoblots_NNS obtained_VBN with_IN supernatants_NNS from_IN cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS (_( day_NN 17_CD after_IN vaccination_NN )_) cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NNS without_IN treatment_NN (_( A_NP )_) or_CC treated_VBN with_IN IFN-gamma_NP (_( B_NP )_) or_CC anti-IFN-gamma_NP (_( C_NP )_) ._SENT The_DT supernatants_NNS were_VBD diluted_VBN 1:160_CD (_( lanes_NNS I_PP )_) or_CC 1:640_CD (_( lanes_NNS II_NP )_) ._SENT FIG._NN 5_CD ._SENT |_SYM Flow_NP cytometric_JJ analysis_NN of_IN lymph_NN node_NN cells_NNS (_( day_NN 17_CD after_IN vaccination_NN )_) cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP Flow_NP cytometric_JJ analysis_NN of_IN lymph_NN node_NN cells_NNS (_( day_NN 17_CD after_IN vaccination_NN )_) cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP in_IN the_DT presence_NN of_IN isotype-nonspecific_JJ antibody_NN (_( A_NP )_) ,_, rIFN-gamma_NP (_( B_NP )_) ,_, or_CC anti-IFN-gamma_NP (_( C_NP )_) for_IN 4_CD days_NNS ._SENT The_DT cells_NNS were_VBD labeled_VBN with_IN both_DT phycoerythrin-conjugated_JJ anti-murine_NN CD3_NP (_( T_NN cells_NNS )_) and_CC fluorescein_NN isothiocyanate-conjugated_VBN anti-murine_NP CD45R/B220_NP (_( B_NP cells_NNS )_) ._SENT Viability_NN was_VBD determined_VBN by_IN exclusion_NN of_IN propidium_NN iodide_NN ._SENT FIG._NN 6_CD ._SENT |_SYM Macrophages_NP (_( adherent_JJ cells_NNS )_) detected_VBN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP Macrophages_NP (_( adherent_JJ cells_NNS )_) detected_VBN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS cultured_VBN with_IN macrophages_NNS and_CC B._NP burgdorferi_NP and_CC treated_VBN with_IN isotype-nonspecific_JJ antibody_NN (_( A_NP )_) or_CC rIFN-gamma_NP (_( B_NP )_) for_IN 4_CD days_NNS after_IN removal_NN of_IN nonadherent_JJ cells_NNS ._SENT Macrophages_NNS detected_VBN in_IN cultures_NNS of_IN lymph_NN node_NN cells_NNS treated_VBN with_IN anti-IFN-gamma_NP were_VBD similar_JJ to_TO those_DT pictured_VBN in_IN panel_NN A._NP B._NP burgdorferi_NP organisms_NNS are_VBP easily_RB killed_VBN when_WRB they_PP bind_VBP specific_JJ antibody_NN that_WDT activates_VBZ complement_NN ._SENT Several_JJ outer_JJ surface_NN proteins_NNS of_IN B._NP burgdorferi_NP ,_, including_VBG OspA_NP ,_, OspB_NP ,_, OspC_NP ,_, and_CC the_DT 39-kDa_JJ protein_NN (_( ,_, ,_, -_: ,_, )_) ,_, induce_VB complement-dependent_JJ borreliacidal_JJ antibody_NN ._SENT This_DT feature_NN makes_VBZ these_DT outer_JJ surface_NN proteins_VBZ ideal_JJ candidates_NNS for_IN development_NN of_IN a_DT vaccine_NN to_TO prevent_VB infection_NN with_IN B._NP burgdorferi_NP ._SENT Of_IN these_DT proteins_NNS ,_, OspA_NP has_VBZ been_VBN used_VBN to_TO vaccinate_VB humans_NNS and_CC animals_NNS ._SENT Although_IN rOspA_NN is_VBZ immunogenic_JJ ,_, the_DT antibody_NN response_NN is_VBZ dominated_VBN by_IN production_NN of_IN antibody_NN that_WDT is_VBZ not_RB protective_JJ ._SENT Most_RBS importantly_RB ,_, vaccinated_VBD animals_NNS challenged_VBN with_IN B._NP burgdorferi_NNS during_IN periods_NNS with_IN concomitant_JJ high_JJ levels_NNS of_IN nonbactericidal_JJ anti-OspA_NN and_CC low_JJ levels_NNS of_IN anti-OspA_NP borreliacidal_JJ antibodies_NNS develop_VBP arthritis_NN ._SENT Recently_RB ,_, we_PP showed_VBD that_IN hamsters_NNS vaccinated_VBN with_IN 30_CD ,_, 60_CD ,_, or_CC 120_CD mug_NN of_IN rOspA_NN with_IN or_CC without_IN alum_NN developed_VBD severe_JJ destructive_JJ arthritis_NN when_WRB challenged_VBN with_IN B._NP burgdorferi_NP ._SENT Similarly_RB ,_, hamsters_NNS vaccinated_VBD with_IN a_DT commercially_RB available_JJ canine_JJ rOspA_NN vaccine_NN developed_VBD severe_JJ destructive_JJ arthritis_NN after_IN challenge_NN with_IN the_DT Lyme_NP spirochete_NN ._SENT Only_RB the_DT presence_NN of_IN high_JJ levels_NNS of_IN borreliacidal_JJ antibody_NN prevented_VBD infection_NN with_IN B._NP burgdorferi_NP from_IN inducing_VBG arthritis_NN in_IN vaccinated_VBN animals_NNS ._SENT Maximum_JJ protection_NN due_JJ to_TO borreliacidal_JJ antibody_NN ,_, however_RB ,_, is_VBZ restricted_VBN to_TO 7_CD to_TO 9_CD weeks_NNS after_IN vaccination_NN ._SENT One_CD approach_NN to_TO increase_VB the_DT duration_NN of_IN protection_NN and_CC lessen_VB the_DT potential_NN for_IN adverse_JJ effects_NNS is_VBZ to_TO determine_VB the_DT immune_JJ mediators_NNS responsible_JJ for_IN the_DT production_NN and_CC maintenance_NN of_IN borreliacidal_JJ antibody_NN ._SENT We_PP showed_VBD previously_RB that_IN IL-4_NN does_VBZ not_RB augment_VB the_DT production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN ,_, even_RB though_IN IL-4_NN is_VBZ known_VBN to_TO up-regulate_VB B-lymphocyte_NN growth_NN and_CC differentiation_NN ._SENT In_IN fact_NN ,_, IL-4_NN inhibited_VBD the_DT production_NN of_IN anti-OspA_NP borreliacidal_JJ antibody_NN ,_, including_VBG IgG2a_NP ,_, by_IN lymph_NN node_NN cells_NNS obtained_VBN from_IN vaccinated_VBN mice_NNS ._SENT It_PP is_VBZ known_VBN that_IN IgG2a_NP is_VBZ negatively_RB regulated_VBN by_IN IL-4_NN but_CC up-regulated_JJ by_IN IFN-gamma_NP ._SENT Our_PP$ data_NNS and_CC those_DT of_IN others_NNS suggested_VBD that_IN IL-4_NN counteracted_VBD the_DT effects_NNS of_IN IFN-gamma_NP on_IN the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT When_WRB lymph_NN node_NN cells_NNS producing_VBG borreliacidal_JJ antibody_NN were_VBD exposed_VBN to_TO rIFN-gamma_NNS ,_, borreliacidal_JJ antibody_NN production_NN was_VBD inhibited_VBN ._SENT The_DT time_NN of_IN exposure_NN (_( 10_CD min_NN to_TO 4_CD days_NNS )_) of_IN immune_JJ lymph_NN node_NN cells_NNS to_TO rIFN-gamma_NNS did_VBD not_RB affect_VB the_DT inhibition_NN of_IN production_NN of_IN borreliacidal_JJ antibody_NN ._SENT In_IN addition_NN ,_, treatment_NN with_IN rIFN-gamma_NNS inhibited_VBD the_DT production_NN of_IN other_JJ anti-B_NN ._SENT burgdorferi_NN antibodies_NNS ._SENT The_DT suppression_NN of_IN borreliacidal_JJ and_CC other_JJ anti-B_NN ._SENT burgdorferi_NN antibodies_NNS by_IN rIFN-gamma_NNS was_VBD unexpected_JJ ._SENT Flow_NN cytometric_JJ analysis_NN of_IN rIFN-gamma-treated_JJ and_CC untreated_JJ immune_JJ lymph_NN node_NN cells_NNS showed_VBD that_DT treatment_NN with_IN rIFN-gamma_NNS reduced_VBD the_DT number_NN of_IN viable_JJ lymphocytes_NNS ,_, especially_RB B_NP lymphocytes_NNS ._SENT In_IN addition_NN ,_, macrophages_NNS cultured_VBN in_IN the_DT presence_NN of_IN exogenous_JJ rIFN-gamma_NNS were_VBD rounded_VBN and_CC exhibited_VBN rare_JJ pseudopodia_NNS ._SENT By_IN contrast_NN ,_, macrophages_NNS obtained_VBN from_IN cultures_NNS of_IN untreated_JJ lymph_NN node_NN cells_NNS producing_VBG borreliacidal_JJ antibody_NN were_VBD spindle_NN shaped_VBN with_IN many_JJ pseudopodia_NNS ._SENT IFN-gamma_NP has_VBZ been_VBN shown_VBN to_TO induce_VB apoptosis_NN in_IN T_NN and_CC B_NN lymphocytes_NNS ._SENT These_DT events_NNS could_MD have_VB affected_VBN the_DT activation_NN of_IN macrophages_NNS and_CC their_PP$ ability_NN to_TO process_VB borrelial_JJ antigen_NN ._SENT It_PP is_VBZ possible_JJ that_IN inhibition_NN of_IN borreliacidal_JJ antibody_NN was_VBD due_JJ to_TO the_DT use_NN of_IN toxic_JJ concentrations_NNS of_IN rIFN-gamma_NNS ._SENT However_RB ,_, when_WRB more_JJR physiologically_RB relevant_JJ concentrations_NNS (_( 1.0_CD or_CC 0.1_CD mug_NN )_) of_IN rIFN-gamma_NNS were_VBD added_VBN to_TO immune_JJ lymph_NN node_NN cells_NNS ,_, borreliacidal_JJ activity_NN also_RB failed_VBD to_TO increase_VB ._SENT In_IN addition_NN ,_, immune_JJ lymph_NN node_NN cells_NNS were_VBD treated_VBN with_IN anti-CD119_NN ,_, which_WDT blocks_VBZ the_DT binding_NN of_IN murine_JJ IFN-gamma_NP to_TO cellular_JJ receptors_NNS ._SENT No_DT significant_JJ decrease_NN in_IN borreliacidal-antibody_NN production_NN was_VBD detected_VBN in_IN these_DT cultures_NNS compared_VBN to_TO immune_JJ lymph_NN node_NN cells_NNS treated_VBN with_IN an_DT isotype-nonspecific_JJ antibody_NN (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS suggest_VBP that_IN IFN-gamma_NP is_VBZ not_RB a_DT major_JJ force_NN in_IN driving_VBG the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT Perhaps_RB the_DT most_RBS compelling_JJ evidence_NN that_IN IFN-gamma_NP is_VBZ not_RB responsible_JJ for_IN production_NN of_IN borreliacidal_JJ antibody_NN came_VBD from_IN experiments_NNS utilizing_VBG neutralizing_VBG antibody_NN to_TO IFN-gamma_NP ._SENT Treatment_NN of_IN immune_JJ lymph_NN node_NN cells_NNS with_IN various_JJ concentrations_NNS of_IN anti-IFN-gamma_NP failed_VBD to_TO suppress_VB borreliacidal_JJ activity_NN ._SENT In_IN fact_NN ,_, borreliacidal_JJ antibody_NN production_NN was_VBD marginally_RB enhanced_VBN ,_, especially_RB when_WRB treatment_NN with_IN anti-IFN-gamma_NP occurred_VBD early_RB in_IN cultivation_NN of_IN the_DT immune_JJ lymph_NN node_NN cells_NNS ._SENT Furthermore_RB ,_, treatment_NN with_IN anti-IFN-gamma_NNS resulted_VBN in_IN polyclonal_JJ expansion_NN of_IN the_DT anti-B_NN ._SENT burgdorferi_NP antibody_NN response_NN ._SENT In_IN support_NN of_IN this_DT idea_NN ,_, by_IN using_VBG flow_NN cytometric_JJ analysis_NN ,_, we_PP also_RB detected_VBD a_DT significant_JJ increase_NN in_IN the_DT number_NN of_IN B_NP lymphocytes_NNS in_IN cultures_NNS of_IN immune_JJ lymph_NN node_NN cells_NNS treated_VBN with_IN anti-IFN-gamma_NP ._SENT IFN-gamma_NP performs_VBZ numerous_JJ immunologic_JJ functions_NNS ,_, including_VBG T_NN helper_NN lymphocyte_NN differentiation_NN and_CC stabilization_NN ,_, enhancement_NN of_IN major_JJ histocompatibility_NN complex_JJ expression_NN on_IN both_DT B_NP lymphocytes_NNS and_CC macrophages_NNS ,_, antiviral_JJ effects_NNS ,_, and_CC amelioration_NN of_IN production_NN of_IN IgG2a_NP ._SENT Our_PP$ results_NNS ,_, however_RB ,_, show_VBP that_IN IFN-gamma_NP suppresses_VBZ antibody_NN production_NN ,_, including_VBG IgG2a_NP borreliacidal_JJ antibody_NN ._SENT An_DT explanation_NN may_MD be_VB that_DT IgG2a_NP antibody_NN expression_NN is_VBZ not_RB completely_RB dependent_JJ upon_IN IFN-gamma_NP ._SENT In_IN addition_NN ,_, IFN-gamma_NP may_MD prevent_VB the_DT expression_NN of_IN IL-4_NN functions_NNS ._SENT However_RB ,_, we_PP showed_VBD previously_RB that_IN IL-4_NN suppressed_VBD the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT This_DT suggests_VBZ that_IN other_JJ cytokines_NNS ,_, but_CC not_RB IL-4_NN or_CC IFN-gamma_NP ,_, may_MD be_VB responsible_JJ for_IN the_DT induction_NN ,_, production_NN ,_, and_CC maintenance_NN of_IN borreliacidal_JJ antibody_NN ._SENT In_IN support_NN of_IN this_DT idea_NN ,_, treatment_NN with_IN anti-IFN-gamma_NNS augmented_VBN not_RB only_RB borreliacidal_JJ antibody_NN but_CC other_JJ antibodies_NNS directed_VBN against_IN B._NP burgdorferi_NP ._SENT Additional_JJ studies_NNS are_VBP needed_VBN to_TO determine_VB which_WDT cytokines_NNS are_VBP responsible_JJ for_IN the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT In_IN conclusion_NN ,_, we_PP showed_VBD that_IN IFN-gamma_NP plays_VBZ a_DT major_JJ role_NN in_IN suppression_NN of_IN the_DT production_NN of_IN borreliacidal_JJ antibody_NN ._SENT Effective_JJ neutralization_NN of_IN endogenous_JJ IFN-gamma_NP slightly_RB augmented_VBD the_DT production_NN of_IN borreliacidal_JJ antibody_NN and_CC expanded_VBD the_DT anti-B_NN ._SENT burgdorferi_NN antibody_NN responses_NNS ._SENT Determination_NN of_IN the_DT mechanism_NN that_WDT inhibits_VBZ the_DT production_NN of_IN borreliacidal_JJ antibody_NN by_IN rIFN-gamma_NNS may_MD lead_VB to_TO the_DT development_NN of_IN a_DT safe_JJ and_CC effective_JJ Lyme_NP borreliosis_NN vaccine_NN ._SENT 